Table 2.
Incidences of infusion-associated reactions according to treatment course
| 1st course | 2nd course | 3rd course | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Any infusion-associated reaction | 102 | 84.3 | 59 | 57.3 | 4 | 57.1 |
| Urticaria or rash | 63 | 52.1 | 22 | 21.3 | 1 | 14.3 |
| Headache | 22 | 18.2 | 20 | 19.4 | 1 | 14.3 |
| Hyperthermia or fever | 18 | 14.9 | 13 | 12.6 | 2 | 28.6 |
| Alterations in heart rate or palpitations | 21 | 17.4 | 9 | 8.7 | 0 | |
| Neurological symptoms | 19 | 15.7 | 8 | 7.8 | 0 | |
| Serious infusion-associated reaction | 13 | 10.7 | 3 | 2.9 | 0 | |
| Patients receiving alemtuzumab in each course | 121 | 103 | 7 | |||
Only the most frequently observed symptoms or findings are presented separately